Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04084171 · ClinicalTrials.gov registry record · NA
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
A NA study, sponsored by University of Virginia.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT04084171: Completed NA study, sponsored by University of Virginia.
NCT04084171 is a NA study that has completed, run by University of Virginia. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04084171, a NA study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
A single-arm, multi-center, clinical study to assess the safety profile of the Tandem t:slim X2 with Control-IQ system in children with T1D aged 2-6 years old under free living condition
Primary Outcome
Percentage of subjects with less than 6% time below 70mg/dL and less than 40% time above 180mg/dL.
Interventions
- DEVICE Tandem t:slim X2 with Control-IQ Technology + Dexcom G6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-09-26 |
| Est. Completion | 2019-10-23 |
| Phase | NA |
What the finished NCT04084171 record still lists
NCT04084171 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 is the first listed.
NCT04084171 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04084171 about?
NCT04084171 is a clinical study titled "Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6". A single-arm, multi-center, clinical study to assess the safety profile of the Tandem t:slim X2 with Control-IQ system in children with T1D aged 2-6 years old under free living condition
What is the current status of trial NCT04084171?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2019-09-26. Estimated completion is 2019-10-23.
What interventions are being tested in trial NCT04084171?
The interventions under investigation include: Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 (DEVICE).
Who is sponsoring clinical trial NCT04084171?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04084171's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI